ArticleGender medicine2012
Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.
Article in Gender medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00469508 (A Randomized, Double-Blind, Placebo-Controlled Evaluation of Modafinil vs Placebo for the Treatment of Methamphetamine Dependence), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Evaluation of Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Ovarian Hormones and Addictive Behaviour Vulnerability: Insights From Preclinical Studies.Addiction biology · 2025Pooled it
- Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis.Frontiers in psychiatry · 2020Pooled it
- Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2013Trial
- Factors influencing methamphetamine use among Lahu hill tribe youth in Chiang Rai, Thailand: A case‒control study.PloS one · 2026Article
- Modeling methamphetamine use disorder in mammals: Sex differences in behavioral, biochemical, and transcriptional consequences.Advances in pharmacology (San Diego, Calif.) · 2024Article
- The Common Denominators of Parkinson's Disease Pathogenesis and Methamphetamine Abuse.Current neuropharmacology · 2024Review
- Brain-derived neurotrophic factor rs6265 (Val66Met) single nucleotide polymorphism as a master modifier of human pathophysiology.Neural regeneration research · 2023Review
- Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts.Neuroscience and biobehavioral reviews · 2022Review
- Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome.Molecular psychiatry · 2021Article
- Association of PICK1 and BDNF variations with increased risk of methamphetamine dependence among Iranian population: a case-control study.BMC medical genomics · 2021Article
- The Influence of the Val66Met Polymorphism of Brain-Derived Neurotrophic Factor on Neurological Function after Traumatic Brain Injury.Journal of Alzheimer's disease : JAD · 2018Review
- Time-Dependent Serum Brain-Derived Neurotrophic Factor Decline During Methamphetamine Withdrawal.Medicine · 2016Article
- Neuroimaging and genetic risk for Alzheimer's disease and addiction-related degenerative brain disorders.Brain imaging and behavior · 2014Review
- Potentiated striatal dopamine release leads to hyperdopaminergia in female brain-derived neurotrophic factor heterozygous mice.ACS chemical neuroscience · 2014Article
- Pharmacotherapy of amphetamine-type stimulant dependence: an update.Drug and alcohol review · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundFrequency of pretreatment methamphetamine (MA) use is an important predictor of outcomes of treatment for MA dependence. Preclinical studies suggest females self-administer more MA than males, but few clinical studies have examined potential sex differences in the frequency of MA use. Estrogen increases expression of brain-derived neurotrophic factor (BDNF), which has effects on MA-induced striatal dopamine release and protects against MA-induced neurotoxicity.
objectiveWe examined potential effects of sex, the Val66Met polymorphism in BDNF, and their interaction on frequency of MA use among 60 Caucasian MA-dependent volunteers screening for a clinical trial.
methodsData was taken from 60 Caucasian MA-dependent volunteers screening for a clinical trial.
resultsFemales reported significantly more pretreatment days with MA use in the past 30 days than males. There was a significant interaction between sex and BDNF Val66Met, with the highest frequency of MA use among females with Val/Val genotype.
conclusionsThese results, although preliminary, add to the literature documenting sexual dimorphism in response to stimulants, including MA, and suggest a potential biological mechanism involving BDNF that might contribute to these differences. Additional research characterizing the biological basis of altered response to MA among females is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.